Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The company expects the funding to bring it into the clinic and is also in partnering talks with academic institutions and biopharma companies, said co-founder Jonathan Lim, who previously led Ignyta.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.